Panelists Robert A. Figlin, MD; Eric Jonasch, MD; and Toni K. Choueiri, MD, discuss the change over the past decade in terms of available therapies, the new agents that continue to become available, and continuing to refine treating patients with advanced renal cell carcinoma in a more individualized fashion.
Ещё видео!